Showing results (1-10 of 223) with videos related to
Sort By:
Pageof 23
CNS Drugs|July 4, 2018
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An OverviewFloriana De Angelis, Domenico Plantone, Jeremy ChatawayCNS Drugs|May 12, 2016
Secondary Progressive Multiple Sclerosis: Definition and MeasurementDomenico Plantone, Floriana De Angelis, Anisha Doshi, et al.European Journal of Neurology|February 10, 2026
Vascular Comorbidities and an Increased Comorbidity Score Are Associated With Disability and Disability Progression in Secondary Progressive Multiple SclerosisNevin A John, Yingtong Li, Floriana De Angelis, et al.Multiple Sclerosis and Related Disorders|February 8, 2025
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MSAnisha Doshi, Nils Muhlert, Gloria Castellazzi, et al.European Journal of Neurology|December 18, 2024
Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosisNevin A John, Yingtong Li, Floriana De Angelis, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|January 23, 2025
Neurofilament heavy chain in secondary progressive multiple sclerosisFloriana De Angelis, Francesca Ammoscato, Richard A Parker, et al.Multiple Sclerosis and Related Disorders|June 7, 2022
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trialPeter Foley, Richard A Parker, Floriana de Angelis, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 18, 2024
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trialFloriana De Angelis, James R Cameron, Arman Eshaghi, et al.Trials|August 9, 2022
Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trialsThomas Williams, Sarah Alexander, James Blackstone, et al.Journal of Magnetic Resonance Imaging : JMRI|October 3, 2023
Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective TreatmentsNevin A John, Bhavana S Solanky, Floriana De Angelis, et al.Pageof 23